Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial
Sanjay Ramakrishnan(Oxford BioMedica (United Kingdom)), Mona Bafadhel(National Institute for Health and Care Research), J. Mark Melhorn(University Hospital of Wales), Richard Russell(Southern Health NHS Foundation Trust), Christine Mwasuku(National Institute for Health and Care Research), Mahdi Mahdi(National Institute for Health and Care Research), Ian Pavord(Oxford BioMedica (United Kingdom)), Stefan Peterson(Public Health Agency of Sweden), Karolina Krassowska(National Institute for Health and Care Research), Thomas Bengtsson(WeMind), Hafiz Taha Mahmood(The University of Western Australia), Laura Bermejo-Sanchez(University of Oxford), Imran Howell(Institute of Cancer Research)
Cited by 98
Related Papers
Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals
|Annals of the American Thoracic Society|2018|723
Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma: A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Trial
|American Journal of Respiratory and Critical Care Medicine|2009|686
Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study
|The Lancet Respiratory Medicine|2015|584
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
|New England Journal of Medicine|2023|452
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
|The Lancet Respiratory Medicine|2021|434